Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 296, Issue 3, 2001, Pages 890-897

  Geary, Richard S ^a   Watanabe, Tanya A ^a   Truong, Loanne ^a   Freier, Sue ^a   Lesnik, Elena A ^a   Sioufi, Namir B ^a   Sasmor, Henri ^a   Manoharan, Muthiah ^a   Levin, Arthur A ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; ANTISENSE OLIGONUCLEOTIDE; ISIS 11159; ISIS 14725; ISIS 16952; ISIS 18268; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG PROTEIN BINDING; KIDNEY; MALE; MOLECULAR STABILITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT;

ANIMALS; DEOXYRIBONUCLEASES; DRUG STABILITY; MALE; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; THIONUCLEOTIDES; TISSUE DISTRIBUTION;

EID: 0035119936     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Pharmacokinetics of antisense oligonucleotides
2. Effect of aspirin on protein binding and tissue disposition of oligonucleotide phosphorothioate in rats
3. Second generation of antisense oligonucleotides: From nuclease resistance to biological efficacy in animals
4. 2′-O-(2-methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells
5. Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides
6. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding
7. Phosphorothioate oligodeoxynucleotides distribute similarly in class A scavenger receptor knockout and wild-type mice
8. Antisense medicinal chemistry
9. Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats
10. Pharmacokinetic properties of several novel oligonucleotide analogs in mice
11. Capillary gel electrophoresis and mass spectrometry: Powerful tools for the analysis of antisense oligonucleotides and their metabolites
12. Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice
13. Antisense oligonucleotides to protein kinase C-α and C-raf kinase: Rationale and clinical experience in patients with solid tumors
14. The ups and downs of nucleic acid duplex stability: Structure-stability studies on chemically-modified DNA:RNA duplexes
15. On-line HPLC electrospray mass spectrometry of phosphorothioate oligonucleotide metabolites
16. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression
17. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides
18. Phase I safety and pharmacokinetic profile of an ICAM-1 antisense oligodeoxynucleotide (ISIS 2302)
19. In vivo distribution and metabolism of a phosphorothioate aligonucleotide within rat liver after intravenous administration
20. Tritium labeling of antisense oligonucleotides by exchange with tritiated water
21. Measurement of macromolecular binding using electrospray mass spectrometry. Determination of disassociation constants for oligonucleotide-serum albumin complexes
22. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: Potential mechanism of action
23. Effects of ISIS 2302, a phosphorothioate oligonucleotide, on in vitro and in vivo coagulation parameters
24. Effects of intravenous infusion of phosphorothioate oligonucleotides on coagulation, complement activation and hemodynamics
25. Absorption of antisense oligonucleotides in rat intestine: Effect of chemistry and length
26. Spin probe study of the rotational mobility and intermolecular interactions of serum albumin
27. Quantitation of phosphorothioate oligonucleotides in human plasma
28. A review of issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides
29. The pharmacokinetics and toxicity of phosphorothioate oligonucleotides
30. Nucleocytoplasmic shuttling: A novel in vivo property of antisense phosphorothioate oligodeoxynucleotides
31. 2′-Carbohydrate modifications in antisense oligonucleotide therapy: Importance of conformation, configuration, configuration and conjugation
32. Pulmonary bioavailability of a plosphorothioate oligonucleotide (CGP 64128A): Comparison with other delivery routes
33. Pharmacokinetics, metabolism and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration
34. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate
35. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex
36. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)
37. Shutting down a gene. Antisense drug wins approval
38. In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide
39. Crystal structure and improved antisense properties of 2′-0-(2-methoxyethyl)-RNA
40. Phase I study of an antisense oligonucleotide to protein kinase C-α (ISIS 3521/CGP 64128A) in patients with cancer
41. Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration
42. Evidence for a concentration-dependent polymerization of a commercial human serum albumin